Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ZIO-201 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Single Arm | EXPERIMENTAL | ZIO-201 |
| Name | Type | Description |
|---|---|---|
| ZIO-201 | DRUG | ZIO-201 as a single dose given once every 21 days. This is a dose escalation arm. |
Inclusion Criteria: * Metastatic and /or unresectable disease state after previous standard chemotherapy
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
ZIO-201 is an investigational small molecule being studied for the treatment of advanced sarcoma and advanced cancer. It is currently in Phase 1 clinical development and has not been approved by the FDA.
ZIO-201 is being developed by Alaunos Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol TCRT.
ZIO-201 is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved for commercial use.
ZIO-201 has been studied in two completed Phase 1 clinical trials. One trial (NCT00421135) evaluated the safety and tolerance of intravenous ZIO-201 in patients with advanced cancer, enrolling 30 participants. Another trial (NCT00439686) studied ZIO-201 in advanced sarcoma, enrolling 53 participants.
ZIO-201 is also known as isophosphoramide mustard (IPM). In clinical trials, it has been referred to as intravenous IPM, indicating that ZIO-201 and IPM are the same compound.